33 results

  • Adakveo

    (crizanlizumab)
    Novartis Pharmaceuticals Corporation
    Usage: ADAKVEO® is indicated for reducing the frequency of vaso-occlusive crises (VOCs) in adults and pediatric patients aged 16 and older with sickle cell disease.

  • Afinitor

    (everolimus)
    Novartis Pharmaceuticals Corporation
    Usage: AFINITOR is indicated for: advanced hormone receptor-positive, HER2-negative breast cancer in postmenopausal women; progressive neuroendocrine tumors (PNET and non-functional GI/lung type); advanced renal cell carcinoma (RCC); TSC-associated renal angiomyolipoma; TSC-associated subependymal giant cell astrocytoma (SEGA); and partial-onset seizures related to TSC.

  • Alomide (lodoxamide tromethamine)

    (lodoxamide tromethamine)
    Novartis Pharmaceuticals Corporation
    Usage: ALOMIDE® (lodoxamide tromethamine ophthalmic solution) 0.1% is indicated for treating ocular disorders, specifically vernal keratoconjunctivitis, vernal conjunctivitis, and vernal keratitis.

  • Beovu

    (brolucizumab)
    Novartis Pharmaceuticals Corporation
    Usage: BEOVU® is indicated for the treatment of neovascular (wet) age-related macular degeneration (AMD) and diabetic macular edema (DME).

  • Betoptic s (betaxolol hydrochloride)

    (betaxolol hydrochloride)
    Novartis Pharmaceuticals Corporation
    Usage: BETOPTIC S (betaxolol hydrochloride ophthalmic suspension) 0.25% is indicated for lowering elevated intraocular pressure in patients with chronic open-angle glaucoma or ocular hypertension.

  • Cosentyx

    (secukinumab)
    Novartis Pharmaceuticals Corporation
    Usage: COSENTYX is indicated for the treatment of moderate to severe plaque psoriasis in patients 6 years and older, active psoriatic arthritis in patients 2 years and older, active ankylosing spondylitis in adults, active non-radiographic axial spondyloarthritis in adults, active enthesitis-related arthritis in patients 4 years and older, and moderate to severe hidradenitis suppurativa in adults.

  • Desferal (deferoxamine mesylate)

    (deferoxamine mesylate)
    Novartis Pharmaceuticals Corporation
    Usage: DESFERAL is indicated for treating acute iron intoxication and for managing chronic iron overload in patients with chronic anemia. It is not suitable for primary hemochromatosis, where phlebotomy is preferred.

  • Durezol (difluprednate)

    (difluprednate)
    Novartis Pharmaceuticals Corporation
    Usage: DUREZOL® (difluprednate ophthalmic emulsion) 0.05% is indicated for treating inflammation and pain associated with ocular surgery and for the treatment of endogenous anterior uveitis.

  • Entresto

    (Sacubitril and Valsartan)
    Novartis Pharmaceuticals Corporation
    Usage: ENTRESTO is indicated for reducing cardiovascular death and hospitalization in adults with chronic heart failure, particularly those with reduced left ventricular ejection fraction. It is also used to treat symptomatic heart failure in pediatric patients aged one year and older, aiming to improve cardiovascular outcomes.

  • Extavia

    (Interferon beta-1b)
    Novartis Pharmaceuticals Corporation
    Usage: EXTAVIA is indicated for treating relapsing forms of multiple sclerosis (MS) in adults, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease.